Convalescent Plasma / King Fahad Specialist Hospital - LARVOL DELTA

Perceptions of Saudis Toward Participating in the COVID-19 Convalescent Plasma Clinical Trial. (PubMed, Cureus) - "The gap in knowledge about clinical trials among the participants indicated that certain age groups could be targeted through channels where they communicate the most. Conclusion Engaging the community in clinical trials and educating others about their value by sharing experiences would help promote clinical trials and activate donations."

Journal • Cognitive Disorders • Infectious Disease • Novel Coronavirus Disease

Potential Efficacy of Convalescent Plasma to Treat Severe COVID-19 and Patients at High Risk of Developing Severe COVID-19 (clinicaltrials.gov) - P2; N=575; Completed; Sponsor: King Fahad Specialist Hospital Dammam; Recruiting ➔ Completed

Clinical • Trial completion • Infectious Disease • Novel Coronavirus Disease

[VIRTUAL] A National Collaborative Multicenter Phase II Study for Potential Safety Efficacy of Convalescent Plasma to Treat Severe COVID-19 Patients (ASH 2020) - "Patients who are in the category of life-threating/end organs failure do not seem to benefit. There might be a benefit in the other subgroups."

Clinical • P2 data • Critical care • Diabetes • Hypertension • Infectious Disease • Metabolic Disorders • Novel Coronavirus Disease • Respiratory Diseases • Septic Shock

Potential Efficacy of Convalescent Plasma to Treat Severe COVID-19 and Patients at High Risk of Developing Severe COVID-19 (clinicaltrials.gov) - P2; N=575; Recruiting; Sponsor: King Fahad Specialist Hospital Dammam; N=40 ➔ 575

Clinical • Enrollment change • Infectious Disease • Novel Coronavirus Disease

Potential Efficacy of Convalescent Plasma to Treat Severe COVID-19 and Patients at High Risk of Developing Severe COVID-19 (clinicaltrials.gov) - P2; N=40; Recruiting; Sponsor: King Fahad Specialist Hospital Dammam; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Infectious Disease • Novel Coronavirus Disease

Potential Efficacy of Convalescent Plasma to Treat Severe COVID-19 and Patients at High Risk of Developing Severe COVID-19 (clinicaltrials.gov) - P2; N=40; Not yet recruiting; Sponsor: King Fahad Specialist Hospital Dammam

Clinical • New P2 trial • Infectious Disease • Novel Coronavirus Disease